Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allarity Therapeutics Inc

0.8813
+0.03524.16%
Post-market: 0.8600-0.0213-2.42%19:45 EDT
Volume:346.82K
Turnover:294.36K
Market Cap:13.29M
PE:-0.06
High:0.8899
Open:0.8700
Low:0.8200
Close:0.8461
Loading ...

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

GlobeNewswire
·
13 Mar

Allarity announes Phase 2 trial of stenoparib with temozolomide

TIPRANKS
·
06 Mar

Allarity Therapeutics: Announces Phase 2 Trial of Stenoparib in Combination With Temozolomide for Recurrent Small Cell Lung Cancer

THOMSON REUTERS
·
06 Mar

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

GlobeNewswire
·
06 Mar

BRIEF-Allarity Therapeutics Announces Board Authorization Of $5 Million Share Repurchase Program

Reuters
·
03 Mar

Allarity announces board authorization of $5M share repurchase program

TIPRANKS
·
03 Mar

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

THOMSON REUTERS
·
03 Mar

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

GlobeNewswire
·
03 Mar

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit

THOMSON REUTERS
·
26 Feb

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit

GlobeNewswire
·
26 Feb

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

THOMSON REUTERS
·
24 Feb

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

GlobeNewswire
·
24 Feb

Allarity announces expansion of Phase 2 trial on stenoparib

TIPRANKS
·
06 Feb

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

THOMSON REUTERS
·
06 Feb

Allarity Therapeutics Inc - Patient Enrollment Expected to Begin in First Half of 2025

THOMSON REUTERS
·
06 Feb

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle With SEC

THOMSON REUTERS
·
30 Jan

BRIEF-Allarity Therapeutics To Pay $2.5 Million Civil Penalty

Reuters
·
30 Jan

Allarity Therapeutics Inc - to Pay $2.5 Million Civil Penalty

THOMSON REUTERS
·
30 Jan

Allarity Therapeutics Inc: Has Reached an Agreement in Principle With the SEC Staff to Resolve the Investigation With Respect to the Co

THOMSON REUTERS
·
30 Jan